And the predecessor company FWHT, was what, around $32 or $33 in 2003... That's when FWHT was considered a growth company with revenues north of $200 million ... big LOL!
but the judge did not find him guilt of perjury did she? The Merck employee on the other hand ...
BTW, did you know that GILD has NEVER EVER lost a patent suit to another company -- not even MRK LOL!
" I suspect there will be a pullbacl in stocks than LUV goes below $40"
Mr. Einstein, please look into the camera lens and say "whoops" to the audience...
Well, my dopey friend, don't let facts get in the way of your argument. Nonetheless, here are facts:
January-March on time performance (the most recent ytd data available):
Hey fool,you were comparing DAL with LUV. Two years ago DAL was at 42. It's at 41 today.
Which was the better investment?
BS. Why don't you tell us who has $160 BILLION or so for such a transaction.
By that measure EVERY STOCK in the IBB is broken, too.
When a sector rotation starts, all will improve.
Revenue expectations for 2016 vs 2015 are essentially flat, and at the moment there's nothing to indicate that 2017 will be any different.
BIIB was at about 11x sales before it got hammered.
JNJ's market cap is roughly 4x sales. GILD is roughly 5x sales. Absent some new significant drug(s) in the pipeline, I don't GILD going past a market cap of 10x sales (or 200 billion). CELG is at 11x sales, and I don't think that any other similiar large company is any higher than that.
Gild ain't going to a $450 billion market cap, and probably not to $300 billion, either.
$200 billion, maybe.